OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
Published: 08:33 20 Jul 2026 EDT
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report for the fiscal year ended March 31, 2026, outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead drug candidate.
The clinical-stage biopharmaceutical company said the annual report is available through the SEC and its investor relations website.
Alongside the filing, OKYO highlighted its recent financing activities, noting it raised approximately $25 million during the fiscal year, including a February 2026 public offering that generated about $22 million in gross proceeds, including the exercise of an overallotment option.
"We are pleased to announce the filing of our annual report, which reflects substantial progress across our operations," CFO Keeren Shah wrote in the release.
"During the year we raised approximately $25 million, including the recent capital raise backed by renowned investment funds, which has strengthened our cash position and provides us with ample financial resources to complete the NEPTUNE Phase 3 pivotal trial for urcosimod. This advances us toward potential registration, creating long-term value for patients and shareholders."
The company reported cash and cash equivalents of approximately $20.6 million as of the end of March 2026, which it said is expected to fund operations through completion of the planned global Phase 3 pivotal trial for urcosimod, its investigational treatment for neuropathic corneal pain.
OKYO plans to begin the Phase 3 NEPTUNE trial in the second half of 2026. The study is expected to enroll about 111 patients across the US and Europe, with participants randomized in a 2:1 ratio to receive either 0.05% urcosimod or placebo in a single-dose regimen
The company said the trial design follows positive feedback from the US Food and Drug Administration during a Type D meeting and is intended to serve as a potential registrational study that could support a single-trial approval pathway.
